BLCM : Insider Transactions for Bellicum Pharmaceuticals, Inc | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Bellicum Pharmaceuticals, Inc (BLCM)

$0.07 0.00 (0.00%) as of 4:30 Mon 3/4

Download

Exchange:

N/A

Security Type:

Common

Shares Out:

6,100,000

Market Cap:

455.98(K)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0.0745 - $0.96

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	0	0	0	0
Total Sell Value	$0	$0	$0	$0
Total People Sold	0	0	0	0
Total Sell Transactions	0	0	0	0
End Date	2024-02-01	2023-10-31	2023-05-02	2022-05-02

Adjust Filter Settings

Records found: 179

Page 6 of 8

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Sr. VP and General Counsel

• – –

2016-08-15

4

OE

$7.47

$7,470

D/D

1,000

1,344

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-07-27

4

AS

$15.00

$225,000

I/I

(15,000)

399,982

-

Spencer David M.

Chief Scientific Officer

• – –

2016-07-27

4

AS

$15.00

$150,000

D/D

(10,000)

176,082

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-07-18

4

AS

$13.99

$38,044

D/D

(2,719)

134,206

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-07-15

4

AS

$13.72

$305,677

D/D

(22,281)

136,925

-

Sr. VP and General Counsel

• – –

2016-06-02

4

AS

$13.00

$195,000

D/D

(15,000)

196

-

Sr. VP and General Counsel

• – –

2016-06-02

4

OE

$2.55

$38,250

D/D

15,000

15,196

-

Moseley Annemarie

COO/EVP Clinical Development

• – –

2016-06-02

4

AS

$13.00

$325,000

D/D

(25,000)

251

-

Moseley Annemarie

COO/EVP Clinical Development

• – –

2016-06-02

4

OE

$2.55

$63,750

D/D

25,000

7,016

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-04-22

4

AS

$11.42

$342,788

I/I

(30,000)

414,982

-

Slawin Kevin M.

Chief Technology Officer

• • –

2016-04-22

4

AS

$11.43

$285,710

D/D

(25,000)

159,206

-

10% Owner

– – •

2015-12-24

3

IO

$0.00

$0

I/I

0

4,865,647

-

Spencer David M.

Chief Scientific Officer

• – –

2015-12-14

4

OE

$2.55

$12,750

D/D

5,000

184,559

-

Spencer David M.

Chief Scientific Officer

• – –

2015-12-01

4

AS

$22.95

$114,739

D/D

(5,000)

178,600

-

CFO and Treasurer

• – –

2015-11-24

4

AS

$22.34

$654,459

D/D

(29,300)

88,742

-

Slawin Kevin M.

Chief Technology Officer

• • –

2015-11-16

4

AS

$20.65

$371,632

I/I

(18,000)

398,066

-

Slawin Kevin M.

Chief Technology Officer

• • –

2015-11-16

4

AS

$20.65

$123,877

D/D

(6,000)

184,206

-

Sr. VP and General Counsel

• – –

2015-11-02

4

AS

$13.00

$195,000

D/D

(15,000)

97

-

Sr. VP and General Counsel

• – –

2015-11-02

4

OE

$2.55

$38,250

D/D

15,000

15,097

-

Farrell Thomas J.

President and CEO

• • –

2015-10-01

4

AS

$14.58

$36,442

D/D

(2,500)

63,862

-

Spencer David M.

Chief Scientific Officer

• – –

2015-09-21

4

OE

$2.55

$12,750

D/D

5,000

183,600

-

Spencer David M.

Chief Scientific Officer

• – –

2015-09-11

4

AS

$19.00

$95,000

D/D

(5,000)

178,600

-

Farrell Thomas J.

President and CEO

• • –

2015-09-01

4

AS

$16.78

$41,943

D/D

(2,500)

66,362

-

Farrell Thomas J.

President and CEO

• • –

2015-08-03

4

AS

$20.24

$50,608

D/D

(2,500)

68,862

-

Slawin Kevin M.

Chief Technology Officer

• • –

2015-07-15

4

AS

$20.00

$90,000

I/I

(4,500)

402,066

-

179 Records found	1 2 3 4 5 6 7 8	Page 6 of 8

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.